Abstract
A 87-years-old man with hepatocellular carcinoma (HCC) was treated with surgical resection at 85-years-old. Multiple recurrent HCC was treated with transcatheter arterial chemoembolization (TACE). Because TACE showed unsatisfactory effect, he was treated with sorafenib therapy. Two months after the initiation of sorafenib therapy, dynamic computed tomography (CT) showed decreasement of intratumoral enhancement. However, new lesion was pointed out, and modified RECIST showed progressive disease. Intrahepatic new lesion showed decreasement of intratumoral enhancement. Sorafenib therapy was continued at his request. The next 4 months, CT and PIVKA-II plasma levels did not get worse. Six months after the initiation of the therapy, PIVKA-II plasma levels showed marked elevation, and intrahepatic HCC showed intratumoral enhancement. In this case, sorafenib therapy should not be interrupted at 2 months after the initiation of sorafenib therapy.
